Survival Nomogram for Patients With Thymic Carcinoma

NCT07179341 | Completed

• 1 other identifier: SL-B2024-411-01
• Study Type: interventional
• Target: 156
• Locations: 1 country
• Sites: 1

Brief Summary

Background Thymic carcinoma (TC) is a rare and aggressive mediastinal malignancy with poor prognosis. Our study aimed to develop a nomogram to predict overall survival (OS) of TC patients. Method A total of 156 patients confirmed TC between 1996 and 2023 were selected from our database. They were divided into training cohort, validation cohort one and validation cohort two. A nomogram was constructed based on the risk factors affecting prognosis using a Cox proportional hazards regression model. The discrimination and calibration of the nomogram were evaluated by C-index, AUC and curve of calibration. The three cohorts were divided into low-risk and high-risk subgroups.

Conditions

Thymic Carcinoma

Outcome Measures

Primary Outcomes (1)

• Overall survival

  Overall survival (OS) is the length of time a patient lives after a diagnosis or the start of treatment for a disease, such as cancer

  From date of accepting surgery until the date of final documented or date of death from any cause, whichever came first, assessed up to 325 months

Study Arms (3)

Training cohort

ACTIVE COMPARATOR

156 patients diagnosed with TC accepting surgery

Procedure: Thymectomy for thymic carcinoma

Validation cohort one

PLACEBO COMPARATOR

80 patients range from June 1, 1996, to January 1, 2015 accepting surgery

Procedure: Thymectomy for thymic carcinoma

Validation cohort two

PLACEBO COMPARATOR

76 patients range from January 2, 2015, to July 1, 2023 accepting surgery

Procedure: Thymectomy for thymic carcinoma

Interventions

Thymectomy for thymic carcinoma PROCEDURE

Thymectomy for thymic cancer

Training cohort; Validation cohort one; Validation cohort two

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• The diagnosis of TC in patients should be confirmed through endoscopic tumor biopsy or surgery to obtain tumor tissue for pathological confirmation under light microscope, and even further confirmed through immunohistochemical staining.
• Patients should accept surgery and obtain complete postoperative pathological reports in order to assess Masaoka-Koga staging.
• Patients who accepted surgery should be followed up at least six months or reached the endpoint event.

You may not qualify if:

• The patient had two types of primary tumors concurrently including TC.
• The tumor in the thymus was not primary but metastatic, having originated from a different primary site.
• The patient did not obtain a complete pathological report after surgery.

Sponsors & Collaborators

• Weijie Ye: lead

Study Sites (1)

651 Dongfeng Road East, Yuexiu District, Guangzhou, P.R. China

Guangzhou, Guangdong, China

Location

MeSH Terms

Conditions

Thymoma

Interventions

Thymectomy

Condition Hierarchy (Ancestors)

Neoplasms, Complex and Mixed; Neoplasms by Histologic Type; Neoplasms; Thymus Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Lymphatic Diseases; Hemic and Lymphatic Diseases

Intervention Hierarchy (Ancestors)

Thoracic Surgical Procedures; Surgical Procedures, Operative

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Resident Doctor

Study Record Dates

• First Submitted: September 4, 2025
• First Posted: September 17, 2025
• Study Start: July 9, 2024
• Primary Completion: July 1, 2025
• Study Completion: August 1, 2025
• Last Updated: September 17, 2025

Record last verified: 2025-09

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)